Abstract:An androgen receptor (AR) is an intensively studied treatment target for castration-resistant prostate cancer that is irresponsive to conventional antiandrogen therapeutics. Binding function 3 (BF3) inhibitors with alternative modes of action have emerged as a promising approach to overcoming antiandrogen resistance. However, how these BF3 inhibitors modulate AR function remains elusive, hindering the development of BF3-targeting agents. Here, we performed an integrated computational study to interrogate the binding mechanism of several known BF3 inhibitors with ARs. Our results show that the inhibitory effect of the BF3 antagonists arises from their allosteric modulation of the activation function (AF2) site, which alters the dynamic coupling between the BF3 and AF2 sites as well as the AF2-coactivator (SRC2-3) interaction. Moreover, the per-residue binding energy analyses reveal the "anchor" role of the linker connecting the phenyl ring and benzimidazole/indole in these BF3 inhibitors. Furthermore, the allosteric driver-interacting residues are found to include both "positive", e.g., Phe673 and Asn833, and "negative" ones, e.g., Phe826, and the differential interactions with these residues provide an explanation why stronger binding does not necessarily result in higher inhibitory activities. Finally, our allosteric communication pathway analyses delineate how the allosteric signals triggered by BF3 binding are propagated to the AF2 pocket through multiple short- and/or long-ranged transmission pathways. Collectively, our combined computational study provides a comprehensive structural mechanism underlying how the selected set of BF3 inhibitors modulate AR function, which will help guide future development of BF3 antagonists.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.1c00124?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.1c00124</a>.Structure and biological activity of BF3 antagonists with the benzimidazole scaffold; binding energies including contributions from enthalpy (ΔEele + ΔEvdW + ΔGGB + ΔGSA) and entropy (−TΔS) changes; per-residue binding energies and corresponding components of key residues; binding free energies and the corresponding energy terms of SRC23 peptide with AF2 in BF3 bound and unbound ARs; key residues involved in the interaction between ARs and SRC23; predicted allosteric BF3 → AF2 pathways in androgen-bound ARs by the Monte Carlo (MC) path generation approach; RMSDs of backbone atoms as a function of simulation time for AR/TES/SRC23; structural comparison of the AF2 surfaces; differences in the SRC binding interaction energy contributions of individual AR residues; community structures of residue contact networks; and propensities of residues being sensors/effectors mapped onto ribbon diagrams of AR and the corresponding PRS maps of the BF3 antagonistic AR/TES in complex with BF3 antagonists (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.1c00124/suppl_file/ci1c00124_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

What problem does this paper attempt to address?

The problems that this paper attempts to solve are: How to overcome the resistance of androgen receptor (AR) to traditional anti - androgen therapy by combining the allosteric inhibition of function 3 (BF3) antagonists. Specifically, the research aims to reveal the mechanisms of these BF3 antagonists binding to AR through integrated molecular modeling studies, and how they exert inhibitory effects by changing the kinetic coupling of AR activation function 2 (AF2) sites and their interactions with co - activators (such as SRC2 - 3). In addition, the study also explores the "anchoring" role of the linkers connecting the benzene ring and the benzimidazole/indole moieties in these BF3 antagonists in binding, and how the interactions between different residues affect the relationship between binding affinity and inhibitory activity. Finally, by analyzing allosteric signaling pathways, the study clarifies how allosteric signals triggered by BF3 binding are propagated to the AF2 pocket through multiple short - range or long - range transmission pathways, thereby regulating the function of AR. The solutions to these problems are helpful to guide the future development of BF3 antagonists.

Mechanistic Insights into the Allosteric Inhibition of Androgen Receptors by Binding Function 3 Antagonists from an Integrated Molecular Modeling Study

Synthesis and Modeling of Novel Α-Aminoalkylphosphonate Ester Derivatives As Potent Inhibitors of Prostate-Specific Antigen; A Comparison Study

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation

Communication between the ligand-binding pocket (LBP) and the activation function-2 (AF2) domain of androgen receptor revealed by molecular dynamics simulations.

Communication between the Ligand-Binding Pocket and the Activation Function-2 Domain of Androgen Receptor Revealed by Molecular Dynamics Simulations

Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator

Conformational dynamics of androgen receptors bound to agonists and antagonists

Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer

Combined Ligand/Structure-Based Virtual Screening and Molecular Dynamics Simulations of Steroidal Androgen Receptor Antagonists

Discovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics Simulation

Molecular Mechanism of Bisphenol A on Androgen Receptor Antagonism.

Computational Analysis of Residue-Specific Binding Free Energies of Androgen Receptor to Ligands

Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers

Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays

Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling

Discovery of N -(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2

Structural and Molecular Insights into the Mechanism of Resistance to Enzalutamide by the Clinical Mutants in Androgen Receptor (AR) in Castration-Resistant Prostate Cancer (CRPC) Patients

Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors

Computational Investigation on the Allosteric Modulation of Androgen Receptor

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists

Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists